Peterson has expanded her reach at the world’s largest health care company, adding medical devices to a portfolio that includes brands ranging from Band-Aid to Tylenol. She now oversees some $40 billion in revenue—more than half of J&J’s total. She’s been on an acquisition tear, shepherding six deals in the consumer business in the past 18 months and 23 in medical devices during the first half of 2017. The moves are meant to help transform J&J, whose stock has underperformed the S&P over the past 12 months.
Company Financials (2016, or most recently completed fiscal year)
|Market Value as of 9/14/17 ($M)||360139.1|
3 business lessons from Microsoft's board nominee
We sat down with Sandra Peterson, chairwoman of Johnson & Johnson, at this year’s Most Powerful Women Summit. Here are some lessons she learned over the years.